# Cusatuzumab

Source: https://onco.cc/drugs/cusatuzumab/  
OnCo record `cusatuzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.

## Summary

Cusatuzumab (OV-1001, JNJ-74494550, ARGX-110) is a monoclonal antibody developed by OncoVerity. Its target is CD70. ClinicalTrials.gov describes the intervention as: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in acute myeloid leukaemia. The largest, NCT06384261, plans to enrol 140 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: OV-1001, JNJ-74494550, ARGX-110
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at CD70, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of Cusatuzumab: https://clinicaltrials.gov/search?intr=OV-1001
- Sponsor page: https://www.oncoverity.com

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [CD70](https://onco.cc/targets/cd70/)
- companies: [argenx](https://onco.cc/companies/argenx/), [OncoVerity](https://onco.cc/companies/oncoverity/)
- trials: [A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy](https://onco.cc/trials/nct04023526/)

---
JSON: https://onco.cc/api/v1/entities/cusatuzumab.json